Abbott India Ltd.
ABBOTINDIA · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹17,615.9.
Piotroski F-score 2/9 — quality of earnings & balance sheet.
Investability checklist
- ✓ROE above 15%34.5%
- ✓Low debt (D/E < 0.5)0.04x
- ✓Positive free cash flow
- ✕Revenue growth > 10%7%
- ✓Earnings growing8%
- ✓Net margin ≥ 10%22.4%
- ✓Current ratio > 1.52.55
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✕Above 200-day average
- ✕Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 21.56
- ✕Piotroski ≥ 72/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Strong return on equity (34.5%).
- •Lightly leveraged balance sheet.
- •Healthy profit margin (22.4%).
- •Financially solid — Altman Z 21.56.
Weaknesses
- •Price below its 200-day moving average (downtrend).
- •Weak Piotroski score (2/9).
About Abbott India Ltd.
Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, central nervous system, vaccines, and multispecialty, including insomnia, vitamin D deficiency, pre-term labor, and pain management. It also provides anti-infectives, cardio-diabeto, GI & hepato, hormones, neuro-psychiat, pain management, respiratory, hepatic, neuroscience, metabolics,
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.